Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q92963
UPID:
RIT1_HUMAN
Alternative names:
Ras-like protein expressed in many tissues; Ras-like without CAAX protein 1
Alternative UPACC:
Q92963; B4DQE8; O00646; O00720; Q5VY89; Q5VY90
Background:
GTP-binding protein Rit1, also known as Ras-like protein expressed in many tissues and Ras-like without CAAX protein 1, plays a pivotal role in cellular processes. It is instrumental in linking NGF stimulation to the activation of EPHB2 and MAPK14 signaling pathways, crucial for NGF-dependent neuronal differentiation and ELK1 transactivation via the Ras-MAPK signaling cascade.
Therapeutic significance:
Rit1's involvement in Noonan syndrome 8, characterized by congenital heart defects, hypertrophic cardiomyopathy, and a spectrum of other developmental anomalies, underscores its potential as a therapeutic target. Understanding Rit1's role could pave the way for innovative treatments for Noonan syndrome and related disorders.